Impact of Clostridioides difficile infection on survival and graft-versus-host disease after allogeneic hematopoietic cell transplantation: a multicenter study on behalf of the Polish Adult Leukemia Group
Research Square (Research Square)(2023)
摘要
Abstract Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease (GVHD), including gastrointestinal GVHD (GI-GVHD) is not well established. This multicenter study assessed real-life data on the first-line treatment of CDI and its impact on allo-HCT outcomes. Retrospective and prospective data of patients with CDI after allo-HCT were assessed. The first-line treatment for CDI included metronidazole in 34 patients; vancomycin, in 64; and combination therapy, in 10. Treatment failure was more common with metronidazole than with vancomycin (38.2% vs. 6.2%; P <0.001). The need to administer second-line treatment was associated with the occurrence or exacerbation of GVHD ( P <0.05) and GI-GVHD ( P <0.001) and reduced overall survival ( P <0.05). In the multivariate analysis, the risk of death was associated with acute GVHD presence before CDI (hazard ratio[HR], 3.19; P =0.009) and the need to switch to second-line treatment (HR, 4.83; P <0.001). The efficacy of the initial CDI treatment affects survival and occurrence of immune-mediated GI-GVHD after allo-HCT. Therefore, agents with higher efficacy than metronidazole (vancomycin or fidaxomicin), should be administered as the first-line treatment.
更多查看译文
关键词
allogeneic hematopoietic cell transplantation,clostridioides,leukemia,infection,graft-versus-host
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要